These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 2117288)

  • 1. Immunocytology as a possible marker to identify patients who require prophylaxis.
    Huland H; Schneider A; Huland E; Arndt R
    Prog Clin Biol Res; 1990; 350():35-9. PubMed ID: 2117288
    [No Abstract]   [Full Text] [Related]  

  • 2. BCG-(RIVM) versus mitomycin intravesical therapy in patients with superficial bladder cancer. EORTC GU Group and the Dutch South-East Collaborative Group.
    Debruyne FM; van der Meijden AP; Franssen MP
    Prog Clin Biol Res; 1989; 303():435-46. PubMed ID: 2506556
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of intravesical treatment of transitional cell carcinoma with bacillus Calmette-Guerin and mitomycin C on urinary survivin levels and outcome.
    Hausladen DA; Wheeler MA; Altieri DC; Colberg JW; Weiss RM
    J Urol; 2003 Jul; 170(1):230-4. PubMed ID: 12796695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is there an optimal treatment scheme for adjuvant intravesical therapy? Preliminary analysis of an EORTC protocol comparing early and delayed instillation with and without maintenance of either adriamycin or mitomycin-C in patients with superficial transitional carcinoma of the bladder.
    Kurth KH; Bouffioux C; Sylvester R; de Pauw M
    Prog Clin Biol Res; 1988; 269():525-37. PubMed ID: 3134663
    [No Abstract]   [Full Text] [Related]  

  • 5. [Results of a randomized, double blind prospective study of intravesical chemoprophylaxis with 2 drugs: adriamycin and mitomycin; and 2 ways of initiating the instillations: early and late. Effect on recurrence and progression].
    Iborra Juan I; Ricos Torrent JV; Monrós Lliso JL; Dumont Martínez R; Casanova Ramón-Borja J; Solsona Narbón E
    Arch Esp Urol; 1992 Dec; 45(10):1001-7. PubMed ID: 1294028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Quantitative immunocytology as a marker for indications and follow-up of recurrence prevention of superficial urinary bladder cancers].
    Schneider AW; Huland E; Huland H
    Urologe A; 1989 Sep; 28(5):289-91. PubMed ID: 2815438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravesical chemotherapy.
    Prout GR
    Prog Clin Biol Res; 1984; 162B():125-50. PubMed ID: 6438639
    [No Abstract]   [Full Text] [Related]  

  • 8. Serial urinary IL-2, IL-6, IL-8, TNFalpha, UBC, CYFRA 21-1 and NMP22 during follow-up of patients with bladder cancer receiving intravesical BCG.
    Sanchez-Carbayo M; Urrutia M; Romani R; Herrero M; Gonzalez de Buitrago JM; Navajo JA
    Anticancer Res; 2001; 21(4B):3041-7. PubMed ID: 11712808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis.
    Huncharek M; McGarry R; Kupelnick B
    Anticancer Res; 2001; 21(1B):765-9. PubMed ID: 11299841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
    Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
    Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
    Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale for intravesical chemotherapy in the treatment and prophylaxis of superficial transitional cell carcinoma.
    Soloway MS; Jordan AM; Murphy WM
    Prog Clin Biol Res; 1989; 310():215-36. PubMed ID: 2505268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.
    Divrik RT; Yildirim U; Zorlu F; Ozen H
    J Urol; 2006 May; 175(5):1641-4. PubMed ID: 16600720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravesical mitomycin C for superficial transitional cell carcinoma.
    Bolenz C; Cao Y; Arancibia MF; Trojan L; Alken P; Michel MS
    Expert Rev Anticancer Ther; 2006 Aug; 6(8):1273-82. PubMed ID: 16925493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Recurrence rate in adjuvant local chemotherapy of bladder cancer with mitomycin C].
    Flüchter SH; Harzmann R; Erdmann D; Bichler KH
    Helv Chir Acta; 1982 Aug; 49(3-4):349-52. PubMed ID: 6813293
    [No Abstract]   [Full Text] [Related]  

  • 16. Plasma levels during intravesical instillation of mitomycin-C.
    Kurth KH; de Wall JG; van Oosterom AT; de Jong EA; Tjaden UR
    Prog Clin Biol Res; 1985; 185B():81-93. PubMed ID: 3929272
    [No Abstract]   [Full Text] [Related]  

  • 17. Repeat transurethral resection lowers recurrence rates in T1 bladder tumors, even after intravesical mitomycin C.
    Oosterlinck W
    Nat Clin Pract Urol; 2006 Nov; 3(11):582-3. PubMed ID: 17088923
    [No Abstract]   [Full Text] [Related]  

  • 18. BCG-RIVM intravesical immunoprophylaxis for superficial bladder cancer.
    Debruyne FM; van der Meijden AP; Schreinemachers LM; Geboers AD; Franssen MP; van Leeuwen MJ; Steerenberg PA; de Jong WH; Ruitenberg EJ
    Prog Clin Biol Res; 1988; 269():511-24. PubMed ID: 3134662
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical application of NMP22 in the management of transitional cell carcinoma of the bladder.
    Sawczuk IS; Bagiella E; Sawczuk AT; Yun EJ
    Cancer Detect Prev; 2000; 24(4):364-8. PubMed ID: 11059567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of etoposide orally administered every other day for the prevention of recurrence of bladder tumor].
    Miura K; Yuri Y; Tsukada T
    Gan To Kagaku Ryoho; 1990 Jul; 17(7):1375-7. PubMed ID: 2114830
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.